New York State Common Retirement Fund Sells 6,799 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

New York State Common Retirement Fund lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 5.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 112,926 shares of the medical research company’s stock after selling 6,799 shares during the quarter. New York State Common Retirement Fund’s holdings in Charles River Laboratories International were worth $20,846,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in CRL. Versant Capital Management Inc grew its position in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the period. Pinnacle Bancorp Inc. lifted its stake in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares in the last quarter. Assetmark Inc. lifted its stake in shares of Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares in the last quarter. ORG Wealth Partners LLC acquired a new position in shares of Charles River Laboratories International during the fourth quarter valued at about $56,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Charles River Laboratories International in the 3rd quarter worth about $59,000. Institutional investors own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In related news, COO Birgit Girshick purchased 1,514 shares of the stock in a transaction dated Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of research analyst reports. Robert W. Baird cut their target price on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research note on Thursday. JPMorgan Chase & Co. lowered their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. TD Cowen upped their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Finally, UBS Group reissued a “neutral” rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $195.71.

Charles River Laboratories International Price Performance

CRL opened at $163.11 on Friday. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a market cap of $8.34 billion, a price-to-earnings ratio of 1,087.39, a price-to-earnings-growth ratio of 4.54 and a beta of 1.37. The stock has a fifty day simple moving average of $172.84 and a two-hundred day simple moving average of $188.09. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International’s quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.46 earnings per share. Research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).